Kudo T, Asao A, Tachibana T
Clinical Immunology Section, College of Medical Sciences, Tohoku University, Sendai, Japan.
Tohoku J Exp Med. 1988 Apr;154(4):345-55. doi: 10.1620/tjem.154.345.
We describe a method for production of human monoclonal antibody by a combination of the capacity of Epstein-Barr virus (EBV) to transform human B lymphocytes with somatic cell hybridization, in which a new culture medium, GIT, is used. The transformed B cells from wells positive for anti-purified protein derivative (PPD) fused with a (mouse x human) heteromyeloma line (deficient in hypoxanthine-guanine phosphoribosyl transferase and ouabain-resistant) that had been cultured in GIT medium (Kudo et al. 1987) supplemented with geneticin (antibiotic G418) before cell fusion. The hybrids were selected in GIT medium containing HAT and ouabain (GIT-HAT-O) and cloned by limiting dilution technique by use of GIT medium. According to our method, we obtained higher fusion frequency (1/5.5 x 10(3) vs. 1/1.1 x 10(4)) and higher cloning efficiency (43.3-56.7% vs. 3.3-13.3%) compared with the regular method which used the culture medium containing fetal bovine serum (FBS). Six hybrid clones were consequently obtained and characterized. They produced large amount of specific antibodies (35-170 micrograms/ml) in GIT medium, while establishment of hybrid clones producing specific antibodies by the regular method was unsuccessful. This method will be applicable to any kind of human monoclonal antibody production.
我们描述了一种通过将爱泼斯坦-巴尔病毒(EBV)转化人类B淋巴细胞的能力与体细胞杂交相结合来生产人单克隆抗体的方法,其中使用了一种新的培养基GIT。来自抗纯化蛋白衍生物(PPD)阳性孔的转化B细胞与在细胞融合前已在添加了遗传霉素(抗生素G418)的GIT培养基(Kudo等人,1987年)中培养的(小鼠×人)异源骨髓瘤细胞系(次黄嘌呤-鸟嘌呤磷酸核糖基转移酶缺陷且对哇巴因耐药)融合。杂种细胞在含有次黄嘌呤-氨基蝶呤-胸腺嘧啶核苷(HAT)和哇巴因的GIT培养基(GIT-HAT-O)中进行筛选,并通过使用GIT培养基的有限稀释技术进行克隆。根据我们的方法,与使用含有胎牛血清(FBS)的培养基的常规方法相比,我们获得了更高的融合频率(1/5.5×10³对1/1.1×10⁴)和更高的克隆效率(43.3 - 56.7%对3.3 - 13.3%)。最终获得了六个杂种克隆并对其进行了表征。它们在GIT培养基中产生大量特异性抗体(35 - 170微克/毫升),而通过常规方法建立产生特异性抗体的杂种克隆则未成功。该方法将适用于任何类型的人单克隆抗体生产。